**Core Concept**
Oral contraceptives (OCPs) contain estrogen and progestin, which suppress ovulation, thicken cervical mucus, and alter endometrial lining. They are well-known for reducing the risk of certain gynecological and reproductive malignancies, particularly those linked to unopposed estrogen or hormonal fluctuations.

**Why the Correct Answer is Right**
OCPs reduce the risk of uterine malignancy (by inhibiting endometrial proliferation), fibroadenoma of the breast (due to reduced estrogen exposure), and ovarian carcinoma (by suppressing ovulation and reducing ovarian stimulation). However, **hepatic adenoma** is a benign liver tumor that is **not prevented** by OCPs. In fact, estrogen-containing OCPs may slightly increase the risk of hepatic adenoma, especially in women with underlying liver disease or metabolic conditions.

**Why Each Wrong Option is Incorrect**
Option B: Fibroadenoma breast – OCPs reduce risk by lowering estrogen-driven breast tissue proliferation.
Option C: Carcinoma ovary – OCPs reduce ovarian cancer risk by suppressing ovulation and reducing ovarian stimulation.
Option D: Uterine malignancy – OCPs significantly lower risk by preventing endometrial hyperplasia and proliferation.

**Clinical Pearl / High-Yield Fact**
OCPs are protective against endometrial and ovarian cancers but **do not protect against hepatic adenoma**, and may even increase risk in susceptible individuals. Always assess liver function before prescribing OCPs in women with metabolic or liver disease.

✓ Correct Answer: A. Hepatic adenoma